Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.

  title={Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.},
  author={George K Philips and Michael B. Atkins},
  journal={International immunology},
  volume={27 1},
Despite extensive investigation over the past three decades, cancer immunotherapy has produced limited success, with few agents achieving approval by the Food and Drug Administration and even the most effective helping only a minority of patients, primarily with melanoma or renal cancer. In recent years, immune checkpoints that maintain physiologic self-tolerance have been implicated in the down-regulation of anti-tumor immunity. Efforts to restore latent anti-tumor immunity have focused on… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 10 times over the past 90 days. VIEW TWEETS